Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
LLY

LLY - Eli Lilly & Co Stock Price, Fair Value and News

752.88USD+6.17 (+0.83%)Delayed as of 17 Apr 2024, 02:50 pm ET

Market Summary

LLY
USD752.88+6.17
Delayedas of 17 Apr 2024, 02:50 pm
0.83%

LLY Alerts

  • 1 major insider sales recently.

LLY Stock Price

View Fullscreen

LLY RSI Chart

LLY Valuation

Market Cap

709.5B

Price/Earnings (Trailing)

135.39

Price/Sales (Trailing)

20.79

EV/EBITDA

89.71

Price/Free Cashflow

167.33

LLY Price/Sales (Trailing)

LLY Profitability

EBT Margin

19.21%

Return on Equity

48.65%

Return on Assets

8.19%

Free Cashflow Yield

0.6%

LLY Fundamentals

LLY Revenue

Revenue (TTM)

34.1B

Rev. Growth (Yr)

28.1%

Rev. Growth (Qtr)

-1.53%

LLY Earnings

Earnings (TTM)

5.2B

Earnings Growth (Yr)

13.01%

Earnings Growth (Qtr)

3.9K%

Breaking Down LLY Revenue

52 Week Range

367.35755.40
(Low)(High)

Last 7 days

-1.4%

Last 30 days

-1.0%

Last 90 days

18.7%

Trailing 12 Months

100.5%

How does LLY drawdown profile look like?

LLY Financial Health

Current Ratio

0.94

Debt/Equity

1.7

Debt/Cashflow

0.23

LLY Investor Care

Dividend Yield

0.91%

Dividend/Share (TTM)

6.8

Buy Backs (1Y)

0.01%

Diluted EPS (TTM)

5.8

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202327.7B29.5B32.1B34.1B
202229.3B29.1B29.2B28.5B
202125.5B26.7B27.8B28.3B
202023.1B22.9B23.2B24.5B
201921.6B21.7B21.8B22.3B
201820.4B20.9B21.3B21.5B
201720.9B20.6B20.3B20.0B
201620.2B20.6B20.8B21.2B
201519.6B19.6B19.7B20.0B
201422.2B21.2B20.3B19.6B
201322.6B22.9B23.3B23.1B
201224.0B23.4B22.7B22.6B
201123.4B23.9B24.4B24.3B
201022.3B22.7B22.8B23.1B
200920.6B20.8B21.1B21.8B
2008019.2B19.8B20.4B
200700018.6B
Get all data in R, Python etc through our Historical Stock Data APIs
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Eli Lilly & Co

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 15, 2024
alvarez ralph
acquired
12,012
750
16.00
-
Apr 15, 2024
sulzberger gabrielle
acquired
9,760
750
13.00
-
Apr 15, 2024
johnson kimberly h
acquired
9,760
750
13.00
-
Apr 15, 2024
luciano juan r
acquired
15,015
750
20.00
-
Apr 15, 2024
hedley mary lynne
acquired
9,760
750
13.00
-
Mar 18, 2024
hedley mary lynne
acquired
9,914
762
13.00
-
Mar 18, 2024
luciano juan r
acquired
14,490
762
19.00
-
Mar 18, 2024
johnson kimberly h
acquired
9,914
762
13.00
-
Mar 18, 2024
sulzberger gabrielle
acquired
9,914
762
13.00
-
Mar 18, 2024
alvarez ralph
acquired
11,439
762
15.00
-

1–10 of 50

Which funds bought or sold LLY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 15, 2024
Wealthcare Advisory Partners LLC
added
37.3
3,122,280
6,872,540
 0.22%
Apr 15, 2024
BEACH INVESTMENT COUNSEL INC/PA
unchanged
-
-
2,314,000
 0.28%
Apr 15, 2024
Alhambra Investment Management LLC
reduced
-3.74
88,787
400,649
 0.22%
Apr 15, 2024
Sunbelt Securities, Inc.
added
145
3,013,090
4,337,340
 0.48%
Apr 15, 2024
MATRIX ASSET ADVISORS INC/NY
new
-
231,054
231,054
 0.03%
Apr 15, 2024
Parisi Gray Wealth Management
added
1.38
1,116,080
4,277,490
 1.60%
Apr 15, 2024
Arkfeld Wealth Strategies, L.L.C.
unchanged
-
87,157
485,588
 0.27%
Apr 15, 2024
Wealth Alliance Advisory Group, LLC
added
13.38
1,108,820
3,269,320
 0.76%
Apr 15, 2024
Security National Bank
reduced
-10.4
37,327
227,942
 0.04%
Apr 15, 2024
ASPIRIANT, LLC
added
1.27
144,751
558,597
 0.02%

1–10 of 48

Are Funds Buying or Selling LLY?

Are funds buying LLY calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own LLY
No. of Funds

LLY Alerts

Unveiling Eli Lilly & Co's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
7.54%
71,604,696
SC 13G/A
Feb 09, 2024
pnc financial services group, inc.
5.43%
51,540,105
SC 13G/A
Jan 29, 2024
blackrock inc.
6.8%
64,376,027
SC 13G/A
Jan 26, 2024
lilly endowment inc
10.51%
99,768,810
SC 13G/A
Feb 10, 2023
pnc financial services group, inc.
5.25%
51,829,873
SC 13G/A
Feb 09, 2023
vanguard group inc
7.73%
73,429,863
SC 13G/A
Feb 01, 2023
blackrock inc.
6.9%
65,467,793
SC 13G/A
Jan 25, 2023
lilly endowment inc
10.83%
102,948,810
SC 13G/A
Feb 11, 2022
pnc financial services group, inc.
5.42%
51,888,455
SC 13G/A
Feb 09, 2022
vanguard group inc
7.24%
69,261,754
SC 13G/A

Recent SEC filings of Eli Lilly & Co

View All Filings
Date Filed Form Type Document
Apr 16, 2024
4
Insider Trading
Apr 16, 2024
4
Insider Trading
Apr 16, 2024
4
Insider Trading
Apr 16, 2024
4
Insider Trading
Apr 16, 2024
4
Insider Trading
Apr 11, 2024
PX14A6G
PX14A6G
Apr 04, 2024
PX14A6G
PX14A6G
Mar 28, 2024
PX14A6G
PX14A6G
Mar 28, 2024
PX14A6G
PX14A6G
Mar 28, 2024
PX14A6G
PX14A6G

Peers (Alternatives to Eli Lilly & Co)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
JNJ
348.0B
85.2B
 -8.67% -12.80%
9.9
4.09
 6.46% 95.94%
MRK
316.7B
60.1B
 2.91% 8.74%
867.76
5.27
 1.40% -97.49%
PFE
145.1B
46.5B
 -8.05% -37.62%
-104.48
3.12
 42.59% -114.62%
AMGN
142.4B
28.2B
 -1.17% 7.12%
21.2
5.05
 7.09% 2.52%
GILD
83.9B
27.1B
 -8.64% -19.50%
14.81
3.09
 -0.60% 23.36%
TEVA
14.7B
15.8B
 -2.46% 54.12%
-25.47
0.93
 6.17% 76.47%
MID-CAP
PRGO
4.1B
4.7B
 -1.38% -18.66%
-319.58
0.87
 4.58% 90.97%
ALKS
4.0B
1.7B
 -17.22% -19.16%
11.18
2.39
 49.61% 324.78%
BHC
3.2B
8.8B
 -5.00% 14.25%
-5.39
0.36
 7.79% -163.11%
AMPH
2.0B
644.4M
 -4.97% -2.50%
14.31
3.05
 29.14% 50.51%
SMALL-CAP
TLRY
1.4B
743.2M
 6.36% -26.40%
-4.05
1.92
 24.65% 80.36%
TXMD
22.1M
1.3M
 -20.00% -47.68%
-2.15
0.38
 -98.14% -109.18%
ACRX
17.3M
-
 -11.30% 34.21%
-0.94
0.22
 2882.68% -138.52%
AGRX
1.2M
19.6M
 -27.78% -94.56%
-0.08
0.06
 80.00% 43.08%
ACOR
496.8K
117.6M
 -96.45% -95.94%
0
0
 -0.79% -283.60%

Eli Lilly & Co News

Latest updates
MarketBeat • 2 hours ago
Eli Lilly and Company (NYSE:LLY) Shares Down 0.5%
Schaeffers Research • 4 hours ago
Eli Lilly Stock Pops on Drug Efficacy for Sleep Apnea
Benzinga • 5 hours ago
Why Is Eli Lilly Stock Trading Higher Today? - Eli Lilly and Co (NYSE:LLY)
Seeking Alpha • 7 hours ago
Eli Lilly stock gains as Zepbound succeeds in sleep apnea
Yahoo Finance • 21 hours ago
Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts
MarketWatch • 22 hours ago
Eli Lilly & Co. stock outperforms competitors despite losses on the day
Defense World • 35 hours ago
Eli Lilly and Company (NYSE:LLY) Rating Reiterated by Cantor Fitzgerald
Investor's Business Daily • 11 Apr 2024 • 06:15 pm
Is Eli Lilly Stock A Buy Or A Sell After FDA Delays Its Alzheimer's Drug?
The Motley Fool • 02 Apr 2024 • 07:00 am
Is It Too Late to Buy Eli Lilly Stock?
Forbes • 19 Mar 2024 • 07:00 am
Should You Pick Eli Lilly Stock After A 4x Rise In Three Years?

Eli Lilly & Co Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-1.5%9,3539,4998,3126,9607,3026,9426,4887,8108,0006,7736,7406,8067,4405,7415,4995,8606,1145,4775,6375,0925,638
  S&GA Expenses6.7%1,9251,8041,9251,7491,6431,6141,6251,5581,5921,5781,6861,5761,5541,5691,4491,5501,6981,4121,5861,5171,694
  R&D Expenses---2,3571,9851,9961,8031,7821,6101,8981,7051,6551,6721,7291,4651,3901,3921,5811,3811,4021,2311,392
EBITDA Margin-0.8%0.24*0.24*0.30*0.28*0.29*0.28*0.27*0.29*0.27*0.30*0.32*0.33*---------
Income Taxes-34.2%319485326185159114138151114135204121352229232223167152139170-189
Earnings Before Taxes487.3%2,5094272,0891,5302,0961,5661,0912,0541,8401,2451,5941,4762,4691,4371,6441,6801,6631,4061,466731932
EBT Margin0.3%0.19*0.19*0.25*0.23*0.24*0.22*0.21*0.23*0.22*0.24*0.26*0.28*---------
Net Income3914.8%2,190-57.401,7631,3451,9381,4529531,9031,7261,1101,3901,3552,1171,2081,4121,4571,4961,2541,3274,2421,125
Net Income Margin-1.3%0.15*0.16*0.22*0.21*0.22*0.21*0.20*0.21*0.20*0.22*0.23*0.24*---------
Free Cashflow-114.2%-3112,1906321,7311,1612,2171,1832,5232,1571,6311,7761,697---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets10.5%64,00657,91654,81453,16349,49047,46247,06446,91948,80648,18747,80946,83846,63343,94641,96741,10339,28637,89338,66638,00743,908
  Current Assets11.8%25,72723,00721,33220,81118,03517,64017,11516,96518,45217,80817,29616,60517,46216,24014,58213,99413,71012,66213,45512,59820,550
    Cash Equivalents18.4%2,8192,3812,6953,5462,0672,6172,6232,4593,8193,7883,2203,0023,6573,5952,3651,6992,338-2,2902,0367,321
  Inventory17.8%5,7734,9014,7994,5454,3103,8313,8993,8933,8863,9073,8253,6613,9803,5553,3143,1023,1913,1013,1813,0553,098
  Net PPE8.9%12,91411,86311,27710,54610,1449,3119,1289,1038,9858,9208,8568,6308,6828,2817,9817,8987,8737,8027,8487,7807,996
  Goodwill20.9%4,9404,0854,0794,0734,0733,8923,8923,8923,8923,8843,8843,8773,7673,7263,7233,7793,6793,7733,8203,856-
  Current Liabilities24.1%27,29321,99818,91516,01017,13815,65315,62113,38615,05313,68215,09311,71412,48211,97711,98912,61011,77510,82911,85511,23611,888
  Long Term Debt2.2%18,32117,92418,15818,88114,73814,14414,69215,15315,34615,52214,73716,20016,58716,33515,06413,98213,81813,66213,71813,6109,196
    LT Debt, Non Current2.2%18,32117,92418,15818,88114,73814,14414,69215,15315,34615,52214,73716,20016,58716,33515,06413,98213,81813,66213,71813,6109,196
Shareholder's Equity-4.0%10,77211,2206,94911,19010,65010,0708,5459,3698,9597,7578,53060015.007,1545985,8796,6853,3834,3186079,829
  Retained Earnings0.0%10,31210,31010,36910,63910,04310,0078,5569,3698,9599,6398,5309,1817,8307,1546,6175,8794,9204,9824,3184,87911,396
  Additional Paid-In Capital1.3%7,2507,1606,9496,7936,9216,8296,7466,6566,8336,7586,6696,5796,7796,6996,6296,5566,6856,6096,5355,7576,584
Accumulated Depreciation-100.0%-10,76810,63210,48610,23310,07410,12010,1389,9779,9639,8429,6439,5719,6019,2979,1429,1629,0558,9568,7928,667
Shares Outstanding0.0%900900900901902902900904907908908909---------
Minority Interest5.5%92.0087.0086.0010512696.0011513117619721920118416917911892.0080.0077.0085.001,080
Float---398,291---274,342---193,649---138,907---93,167--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-114.2%-3112,1906321,7311,6632,2171,1832,5232,2621,6311,7761,6971,8151,8072,4953821,9641,5101,0523111,449
  Share Based Compensation-44.2%12021616213193.0085.0092.0010175.0090.0092.0086.0088.0072.0077.0072.0082.0076.0080.0076.0073.00
Cashflow From Investing5.1%-2,924-3,080-459-688-943-955-826-1,037-484-616-483-1,283-674-313-210-1,060-41.40-42361.00-7,678-659
Cashflow From Financing519.7%3,545572-1,033412-1,141-1,263-123-2,878-1,526-463-1,083-1,058-1,291-279-1,673107-1,113-1,692-8851,368-1,639
  Dividend Payments0.2%1,0181,0161,0181,017884882884886773770768775670672674671587587598637573
  Buy Backs----750---1,500750-500----500300600-3,5001,100

LLY Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Revenue (Note 2)$ 34,124.1$ 28,541.4$ 28,318.4
Costs, expenses, and other:   
Cost of sales7,082.26,629.87,312.8
Research and development9,313.47,190.86,930.7
Marketing, selling, and administrative7,403.16,440.46,431.6
Acquired in-process research and development (Note 3)3,799.8908.5970.1
Asset impairment, restructuring, and other special charges (Note 5)67.7244.6316.1
Other—net, (income) expense (Note 18)(96.7)320.9201.6
Costs, expenses, and other27,569.521,735.022,162.9
Income before income taxes6,554.66,806.46,155.5
Income taxes (Note 14)1,314.2561.6573.8
Net income$ 5,240.4$ 6,244.8$ 5,581.7
Earnings per share:   
Basic (in dollars per share)$ 5.82$ 6.93$ 6.15
Diluted (in dollars per share)$ 5.80$ 6.90$ 6.12
Shares used in calculation of earnings per share:   
Basic (in shares)900,181901,736906,963
Diluted (in shares)903,284904,619911,681

LLY Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current Assets  
Cash and cash equivalents (Note 7)$ 2,818.6$ 2,067.0
Short-term investments (Note 7)109.1144.8
Accounts receivable, net of allowances of $14.8 (2023) and $16.0 (2022)9,090.56,896.0
Other receivables2,245.71,662.9
Inventories (Note 6)5,772.84,309.7
Prepaid expenses5,540.82,946.8
Other current assets149.57.3
Total current assets25,727.018,034.5
Investments (Note 7)3,052.22,901.8
Goodwill (Note 8)4,939.74,073.0
Other intangibles, net (Note 8)6,906.67,206.6
Deferred tax assets (Note 14)5,477.32,792.9
Property and equipment, net (Note 9)12,913.610,144.0
Other noncurrent assets4,989.94,337.0
Total assets64,006.349,489.8
Current Liabilities  
Short-term borrowings and current maturities of long-term debt (Note 11)6,904.51,501.1
Accounts payable2,598.81,930.6
Employee compensation1,650.41,059.8
Sales rebates and discounts11,689.08,784.1
Dividends payable1,169.21,017.2
Other current liabilities3,281.32,845.4
Total current liabilities27,293.217,138.2
Noncurrent Liabilities  
Long-term debt (Note 11)18,320.814,737.5
Accrued retirement benefits (Note 15)1,438.81,305.1
Long-term income taxes payable (Note 14)3,849.23,709.6
Other noncurrent liabilities2,240.61,824.0
Total noncurrent liabilities25,849.421,576.2
Commitments and Contingencies (Note 16)
Eli Lilly and Company Shareholders' Equity (Notes 12 and 13)  
Common stock—no par value Authorized shares: 3,200,000 Issued shares: 949,781 (2023) and 950,632 (2022)593.6594.1
Additional paid-in capital7,250.46,921.4
Retained earnings10,312.310,042.6
Employee benefit trust(3,013.2)(3,013.2)
Accumulated other comprehensive loss (Note 17)(4,327.0)(3,844.6)
Cost of common stock in treasury(44.2)(50.5)
Total Eli Lilly and Company shareholders' equity10,771.910,649.8
Noncontrolling interests91.8125.6
Total equity10,863.710,775.4
Total liabilities and equity$ 64,006.3$ 49,489.8

About Eli Lilly & Co

LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
 CEO
 WEBSITElilly.com
 INDUSTRYPharmaceuticals
 EMPLOYEES39000

Eli Lilly & Co Frequently Asked Questions

What is the ticker symbol for Eli Lilly & Co? What does LLY stand for in stocks?

LLY is the stock ticker symbol of Eli Lilly & Co. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Eli Lilly & Co (LLY)?

As of Tue Apr 16 2024, market cap of Eli Lilly & Co is 709.5 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LLY stock?

You can check LLY's fair value in chart for subscribers.

What is the fair value of LLY stock?

You can check LLY's fair value in chart for subscribers. The fair value of Eli Lilly & Co is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Eli Lilly & Co is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LLY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Eli Lilly & Co a good stock to buy?

The fair value guage provides a quick view whether LLY is over valued or under valued. Whether Eli Lilly & Co is cheap or expensive depends on the assumptions which impact Eli Lilly & Co's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LLY.

What is Eli Lilly & Co's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, LLY's PE ratio (Price to Earnings) is 135.39 and Price to Sales (PS) ratio is 20.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LLY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Eli Lilly & Co's stock?

In the past 10 years, Eli Lilly & Co has provided 0.312 (multiply by 100 for percentage) rate of return.